The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | MAIC of epcoritamab with R-squared versus tafasitamab with R-squared in 2L+ follicular lymphoma
Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, discusses a match-adjusted indirect comparison (MAIC) of epcoritamab with rituximab plus lenalidomide (R-squared) versus tafasitamab with R-squared in second-line and later (2L+) follicular lymphoma (FL). Dr Vose highlights that this analysis is hypothesis-generating and suggests that epcoritamab may offer improved outcomes over tafasitamab in this patient population; however, a prospective randomized trial would be needed to confirm this. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This was a matched analysis, so it’s not a prospective randomized trial. It’s matching patients from the two different studies and then looking at the outcomes for those patients. So the R-squared part of course is identical and then the two additions, either epcoritamab or the tafasitamab are the differences between the two sides. The patients were fairly well matched with respect to patient characteristics as far as age of patients and extent of lymphoma, et cetera...
This was a matched analysis, so it’s not a prospective randomized trial. It’s matching patients from the two different studies and then looking at the outcomes for those patients. So the R-squared part of course is identical and then the two additions, either epcoritamab or the tafasitamab are the differences between the two sides. The patients were fairly well matched with respect to patient characteristics as far as age of patients and extent of lymphoma, et cetera. And the outcomes showed that the patients that were in the R-squared plus epcoritamab arm, if you will, had a little bit better outcomes with respect to some response rates and the event-free survival. However, again, this is not a randomized study. That’s not something that we necessarily would compare on an everyday basis, but at least is a hypothesis generating in that perhaps the addition of the epcoritamab was an improvement over that of the currently available tafasitamab in that patient population. But only a prospective randomized trial would really be appropriate to say that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory Board: GenMab, Abbvie.
